Showing 911-920 of 9716 results for "".
The Great Imitator: Pruritic Papules in the Setting of HIV
https://practicaldermatology.com/topics/clinical-case-reports/great-imitator-pruritic-papules-setting-hiv/26953/The Great Imitator: Pruritic Papules in the Setting of HIVSafe, Effective Treatments for Hair Loss
https://practicaldermatology.com/topics/hair-nails/safe-effective-treatments-for-hair-loss/26951/Safe, Effective Treatments for Hair LossSCALE 2024: Dr. Michelle Henry on Innovative Skincare Products and Lasers in Skin of Color
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michelle-henry-innovative-skincare-products-and-lasers-skin-color/26374/Michelle Henry, MD, discusses innovative skincare products and lasers in skin of color, including her top 10 tips for ensuring best outcomes and reducing adverse events, at Music City SCALE.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Achieve Skin Tightening in 1-2-3
https://practicaldermatology.com/conferences/maui-derm-2024/achieve-skin-tightening-in-1-2-3/20239/Mitchel P. Goldman, MD, Founder and Medical Director, Cosmetic Laser Dermatology, and Medical Director, Platinum Dermatology Partners, explains the three basic technologies he swears by to tighten skin.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Guselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Of Sharks and Sunscreen
https://practicaldermatology.com/series/scientifically-speaking/of-sharks-and-sunscreen/20130/Often called on to judge "Shark Tank"-style competitions, Humberto Antunes has an eye for what makes an idea work. He talks with host Joel L. Cohen, MD about ingredients for success and also offers insight on sunscreen access in the US.Personalized Skincare: What Women Want!
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/personalized-skincare-what-women-want/23750/A look at emerging approaches for delivering personalized skincare.Stay Relevant with Education
https://practicaldermatology.com/series/dermatology-education-foundation/stay-relevant-with-education/19989/Feed yourself new information and stay on top of data regarding new and existing medications in order to offer patients the best care possible, says Wendy Cantrell, CRNP, DNP. This is particularly important as new understanding of conditions like psoriasis and atopic dermatitis evolve and new treatm